Coherus Oncology (CHRS) Free Cash Flow (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Free Cash Flow data on file, last reported at -$57.9 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 89.51% year-over-year to -$57.9 million; the trailing twelve-month figure through Mar 2026 stood at $304.5 million (up 750.87% YoY), and the FY2025 full-year result was $331.8 million, up 59.99% from the prior year.
• Free Cash Flow eased to -$57.9 million in Q1 2026, from -$28.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $436.8 million in Q2 2025 to a low of -$100.0 million in Q4 2022.
• A 5-year average of $3.7 million and a median of -$39.0 million in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow plunged 8343.95% in 2022 and surged 355.63% in 2024, its largest moves.
• Tracing CHRS's Free Cash Flow over 5 years: stood at -$100.0 million in 2022, then surged by 87.03% to -$13.0 million in 2023, then surged by 320.55% to $28.6 million in 2024, then tumbled by 198.2% to -$28.1 million in 2025, then sank by 106.06% to -$57.9 million in 2026.
• Business Quant data shows CHRS's Free Cash Flow at -$57.9 million in Q1 2026, -$28.1 million in Q4 2025, and -$46.3 million in Q3 2025.